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Accepted 23 April 2012Although endometrial polyps are commonly detected in
uterus examinations, adenomyomatous polyps, a kind of
endometrial polyp, are rarely detected. In fact, results of
a previous study showed that only 14 (1.3%) of the 1100 pa-
tients with endometrial polyps were confirmed to have the
adenomyomatous type [1]. Endometrial polyps are usually
asymptomatic; however, patients with large endometrial
polyps may present with abnormal uterine bleeding. Hyster-
oscopic resection is the standard treatment option for endo-
metrial polyps. Hysterectomy has previously been performed
in patients with large adenomyomatous polyps with charac-
teristics that mimic those of leiomyosarcomas [2]. We expe-
rienced a case wherein a woman presented with a large
intramyometrial tumor that shrank after treatment with
a gonadotropin-releasing hormone (GnRH) agonist. A patho-
logical analysis of the tumor after surgical resection revealed
that it was an adenomyomatous polyp. The test results of this
patient imply that the growth of adenomyomatous polyps is
estrogen dependent.
A 31-year-old nulligravida visited our hospital complaining
of abdominal pain. Physical examination, including pelvic
examination, did not indicate any abnormality. Therefore,
a transvaginal ultrasonography scan was performed, which
revealed a hypervascular tumor (dimensions: 5.1  4.7 cm)
occupying the lower half of the uterus (Fig. 1). However, the
tumor characteristics were not similar to those of common
uterine tumors such as leiomyomas, polyps, or carcinomas. A
Doppler ultrasonography scan showed that the tumor had* Corresponding author. Department of Obstetrics and Gynecology, Shin
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E-mail address: M002179@ms.skh.org.tw (J.-L. Hwang).
1028-4559/$ - see front matter Copyright  2013, Taiwan Association of Obstetri
http://dx.doi.org/10.1016/j.tjog.2013.01.016prominent vessels, with the lowest resistance index being 0.54.
An office hysteroscopy was performed; however, the entry of
the hysteroscope into the uterine cavity was hindered because
of the tumor. Because we were unsure of the type of tumor,
a monthly dose of 3.75-mg leuprolide acetate (Leuplin Depot;
Takeda, Fujisawa, Japan) was administered empirically. Con-
sequently, the tumor size shrank to 2.2  1.9 cm after 1 month
of treatment. After 2 months of treatment, the tumor size
further shrank to 1.8  1.4 cm, and the tumor became an
intracavitary tumor with little blood flow (Fig. 2). An office
hysteroscopy was performed, the results of which showedFig. 1. A transvaginal ultrasonography scan with a sagittal view of the uterus.
The fundus is on the left. The mass occupies the lower half of the uterus and
shows heterogeneous echotexture.
cs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
Fig. 2. A transvaginal ultrasonography scan of the uterus, obtained after
administering two doses of leuprolide acetate. The tumor size has shrunk to
1.8  1.4 cm.
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sion of a leiomyoma. Subsequently, a hysteroscopy was per-
formed, and the tumor was excised without any difficulty.
Pathological examination of the excised tumor specimen
indicated that it was an adenomyomatous polyp. The woman
did not experience any pain 1 week after the surgery.
Endometrial polyps are endometrial overgrowths and con-
tain varying proportions of glands, stroma, and blood vessels.
Although the exact cause of the formation of such polyps is
unknown, estrogen has been implicated in their pathogenesis.
Endometrial polyps grow faster during pregnancy. Obesity,
late menopause, estrogen-replacement therapy or oral contra-
ceptive use, and polycystic ovarian syndrome are also risk
factors for endometrial polyps. These polyps contain estrogen
receptors and progesterone receptors, and the concentrations
of these receptors are significantly higher in the glandular
epithelium of endometrial polyps than those in the normal
endometrium [3].
Adenomyomatous polyp of the uterus is a rare type of
polypoid lesion and is characterized by a mixture of myom-
atous stroma and endometrial glands [4,5]. This type of polyp
may be derived from endometrial stroma cells that are capable
of smooth muscle differentiation [2] or may be a variant of
adenomyosis tissue [5]. Patients with adenomyomatous polyps
usually present with vaginal bleeding, menorrhagia, or dys-
menorrhea [5]. The standard treatment of these polyps in-
volves hysteroscopy. Endometrial polyps are usually small, but
adenomyomatous polyps can be as large as 9 cm [5]. Because
of the possibility of malignancy, a hysterectomy or even
a radical hysterectomy has been performed for patients with
large polyps [2,5]. In the case of our patient, the polyp shrank
after she was administered a GnRH agonist, indicating that
GnRH agonists can be a useful pretreatment option forachieving size reduction of adenomyomatous polyps before
their resection, as has been used for leiomyomas.
GnRH agonists induce a state of hypoestrogenism after an
initial flare-up phase, and are therefore used as a pretreatment
option for myomectomy. Pretreatment with GnRH agonists
improves the hemoglobin level, reduces blood loss during
surgery, and reduces uterine and leiomyoma volumes, which
facilitate subsequent surgery [6]. The average reduction in
uterine and leiomyoma volumes is 40e50%, and most of the
reduction occurs in the first 12 weeks [7,8]. The greatest
proportion of shrinkage occurs after the 1st month and sub-
sequently shows a progressive decline [7]. In our patient, the
tumor size shrank to 1.8  1.4 cm with little blood flow, after
administering two doses of GnRH agonist; therefore, we
decided to proceed with the surgery.
The adverse effects of GnRH agonist therapy are caused by
hypoestrogenism and include hot flashes, insomnia, mood
swings, headache, and vaginal dryness. Severe adverse effects
are rare, and only heavy vaginal bleeding due to degenerating
submucosal leiomyomas has been reported [9]. Our patient
only complained of hot flashes after GnRH agonist therapy
and she did not experience any severe adverse effects.
This case report shows that adenomyomatous polyps can
present as hypervascular tumors and that these polyps respond
to GnRH agonist therapy. Furthermore, the findings of our
case report imply that the growth of adenomyomatous polyps
is estrogen dependent.References
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